Core Viewpoint - The company, Xianjian Technology (01302.HK), has received formal notification from the National Medical Products Administration confirming that its Concave Supra integrated arch branch reconstruction system (CSTM stent system) has entered the special review procedure for innovative medical devices. This product is designed for minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers, marking a significant advancement in the field [1]. Group 1 - The CSTM stent system is the world's first integrated arch branch reconstruction solution that does not require brain ischemia, addressing a critical need in vascular surgery and endovascular intervention [1]. - This product is the 17th to enter the special review procedure by the National Medical Products Administration, indicating the company's strong pipeline of innovative medical devices [1]. - The aortic arch region is known for its complex anatomy and unique hemodynamics, making it one of the most challenging areas in vascular surgery [1]. Group 2 - The CSTM stent system was developed in collaboration with Professor Shu Chang from the National Center for Cardiovascular Diseases and Fuwai Hospital, showcasing the company's commitment to partnerships in advancing medical technology [1]. - The system employs a unique groove and integrated structure, fundamentally addressing multiple technical challenges associated with traditional endovascular techniques in arch branch reconstruction [1]. - This innovation provides a systematic, minimally invasive, and safer solution for complex arch lesions, representing a significant leap forward in treatment options [1].

Group 1 - The A-share market saw a strong performance in brain-computer interface concept stocks, with several companies approaching or hitting their daily limit up [1] - Notable gainers included Entropy Technology, which approached a 20% limit up, and Dao's Technology and Yingkang Life, both rising over 13% [1] - Other significant performers included Tom Cat, which increased by over 10%, and Yanshan Technology, which hit a 10% limit up [1] Group 2 - The table lists various companies with their respective stock codes, percentage increase, total market capitalization, and year-to-date performance [2] - Entropy Technology (301330) had a 19.40% increase, with a market cap of 11.7 billion and a year-to-date increase of 50.11% [2] - Dao's Technology (300409) rose by 13.91%, with a market cap of 25.9 billion and a year-to-date increase of 47.49% [2] - Yingkang Life (300143) increased by 13.01%, with a market cap of 10 billion and a year-to-date increase of 35.43% [2] - Other companies like Tom Cat (300459) and Yanshan Technology (002195) also showed significant gains, with year-to-date increases of 29.63% and 60.65% respectively [2]

Core Viewpoint - The A-share market has seen a strong performance in brain-computer interface concept stocks, with several companies approaching or hitting their daily price limits [1] Group 1: Stock Performance - Entropy Technology (熵基科技) approached a 20% daily limit increase, with a rise of 19.40% and a market capitalization of 11.7 billion [2] - Dao's Technology (道氏技术) increased by 13.91%, reaching a market cap of 25.9 billion [2] - Yingkang Life (盈康生命) rose by 13.01%, with a market cap of 10 billion [2] - Tom Cat (汤姆猫) saw a 10.19% increase, with a market cap of 20.9 billion [2] - Rock Mountain Technology (岩山科技) hit a 10% daily limit increase, with a market cap of 64.6 billion [2] - Three Seven Entertainment (三七互娱) approached a 10% daily limit increase, with a rise of 9.97% and a market cap of 66.4 billion [2] - Other notable performers include Aipeng Medical (爱朋医疗) at 9.99%, Lens Technology (蓝思科技) at 9.80%, and Nanjing Panda (南京熊猫) at 9.33% [2] Group 2: Year-to-Date Performance - Entropy Technology has a year-to-date increase of 50.11% [2] - Dao's Technology has risen 47.49% year-to-date [2] - Yingkang Life has a year-to-date increase of 35.43% [2] - Tom Cat has increased by 29.63% year-to-date [2] - Rock Mountain Technology has a significant year-to-date increase of 60.65% [2] - Aipeng Medical has a year-to-date increase of 54.31% [2] - Nanjing Panda has a remarkable year-to-date increase of 63.01% [2] - Other companies like Innovation Medical (创新医疗) and Keda Xunfei (科大讯飞) have year-to-date increases of 74.01% and 19.29%, respectively [2]

| 序号 | | | | | --- | --- | --- | --- | | | 证券代码 ◆ | 证券简称 ◆ | 交易日期⇒ | | 1 | 601318.SH | 中国部安 | 2026-01-09 | | 2 | 002202.SZ | 金风科技 | 2026-01-09 | | ന | 300308.SZ | 中际旭创 | 2026-01-09 | | ব | 300418.SZ | 昆仑万维 | 2026-01-09 | | 5 | 600030.SH | 中信证券 | 2026-01-09 | | 6 | 300136.SZ | 信维通信 | 2026-01-09 | | 7 | 300450.SZ | 先导智能 | 2026-01-09 | | 8 | 002173.SZ | 创新医疗 | 2026-01-09 | | ರಿ | 603179.SH | 新泉股份 | 2026-01-09 | | 10 | 300750.SZ | 宁德时代 | 2026-01-09 | 中泰证券研报表示，中国商业航天正从"探索验证"阶段向"成长爆发"期过渡，行业迎来关键发展拐点。预计在"十五五"期间，随着政 ...

Market Overview - On January 9, the Shanghai Composite Index rose by 0.92%, with the total margin financing balance reaching 26,276.01 billion yuan, an increase of 69.91 billion yuan compared to the previous trading day [1] - The margin financing balance in the Shanghai market was 13,212.13 billion yuan, up by 34.55 billion yuan, while the Shenzhen market's balance was 12,979.40 billion yuan, increasing by 34.76 billion yuan [1] Industry Analysis - Among the industries tracked by Shenwan, 18 sectors saw an increase in financing balance, with the defense and military industry leading with an increase of 20.07 billion yuan [1] - The computer and electric equipment industries also showed significant increases in financing balance, with increases of 13.67 billion yuan and 13.64 billion yuan, respectively [1] Stock Performance - A total of 1,778 stocks experienced an increase in financing balance, accounting for 47.22% of the market, with 440 stocks seeing an increase of over 5% [1] - The stock with the highest increase in financing balance was Innovation Medical, which saw a balance of 612.87 million yuan, a 106.31% increase from the previous day, and its stock price rose by 10.00% [1] - Other notable stocks with significant increases in financing balance included Lifan Holdings and Portong Medical, with increases of 72.42% and 59.20%, respectively [1] Top Gainers and Losers - Among the top 20 stocks with the highest increase in financing balance, the average stock price rose by 5.21%, with the highest gainers being Shaoyang Hydraulic, Yuekang Pharmaceutical, and Guanshang Technology, with increases of 17.84%, 17.13%, and 13.04%, respectively [2] - Conversely, the stocks with the largest declines in financing balance included Tianrun Technology, which saw a decrease of 56.71%, and others like Geli'er and Changjiang Nengke, with declines of 34.23% and 31.56% [5]

龙虎榜上榜 沪深交易所2026年1月9日公布的交易公开信息显示，创新医疗（002173）因日涨幅偏离值达到7%的前5 只证券，日换手率达到20%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月9日收盘，创新医疗(002173)报收于34.64元，上涨10.0%，换手率42.68%，成交量177.67 万手，成交额60.66亿元。 当日关注点 交易信息汇总资金流向 1月9日主力资金净流入1.32亿元；游资资金净流出2.41亿元；散户资金净流入1.09亿元。 来自交易信息汇总：1月9日创新医疗主力资金净流入1.32亿元，同时因日涨幅偏离值达7%及换手 率超20%登龙虎榜。 来自龙虎榜上榜：创新医疗近5个交易日内第2次登上龙虎榜，上榜原因为日涨幅偏离值达到7%且 日换手率达到20%。 ...

Market Overview - On January 9, the Shanghai Composite Index rose by 0.92%, the Shenzhen Component Index increased by 1.15%, and the ChiNext Index went up by 0.77% [1] - A total of 54 stocks appeared on the "Dragon and Tiger List" due to significant price movements, with Kunlun Wanwei (300418.SZ) seeing the highest net inflow of funds at 1.032 billion yuan [1][3] Stock Performance - Kunlun Wanwei closed up by 19.99% with a turnover rate of 16.37%, and it accounted for 10.03% of the total trading volume [1][3] - Other notable stocks included: - Lioo Co., Ltd. (利欧股份) with a 10.03% increase and a net buy of 626.66 million yuan [3] - Zhenlei Technology (臻镭科技) rose by 19% with a net buy of 550.80 million yuan [3][5] - LeiKe Defense (雷科防务) increased by 3.45% with a net buy of 527.70 million yuan [3] Institutional Activity - Institutions participated in 40 stocks on the Dragon and Tiger List, with a total net buy of 542 million yuan, buying 22 stocks and selling 18 [4] - The stock with the highest institutional net buy was Zhenlei Technology, which saw a net buy of 42.24 million yuan [5][13] Northbound Capital - Northbound funds participated in 28 stocks on the Dragon and Tiger List, with a total net buy of 1.228 billion yuan [8] - The stock with the highest net buy from northbound funds was Innovation Medical (创新医疗), with a net buy of 288 million yuan [8][11] Notable Sell-offs - The stock with the highest net sell was Xue Ren Group (雪人集团), with a net sell of 588.52 million yuan, despite a closing increase of 1.7% [4][11] - Other significant net sells included: - Jin Feng Technology (金风科技) with a net sell of 476.88 million yuan [11][14] - Hongyuan Green Energy (弘元绿能) with a net sell of 342.74 million yuan [4][14]

Core Viewpoint - Innovation Medical experienced a significant trading day with a closing limit up, a turnover rate of 42.68%, and a transaction amount of 6.066 billion yuan, indicating strong market interest and activity [2]. Group 1: Trading Activity - The stock was listed on the Dragon and Tiger list due to a daily price deviation of 8.66% and a turnover rate of 42.65% [2]. - Institutional investors net bought 105 million yuan, while the Shenzhen Stock Connect saw a net purchase of 288 million yuan [2]. - The top five trading departments had a total transaction amount of 1.287 billion yuan, with a net buying amount of 301 million yuan [2]. Group 2: Institutional and Retail Participation - Among the trading departments, one institutional seat was noted, with a net purchase of 105 million yuan, while the Shenzhen Stock Connect was both the largest buyer and seller [2]. - The largest buying department was the Shenzhen Stock Connect with a purchase amount of 436.53 million yuan and a selling amount of 148.45 million yuan [3]. Group 3: Recent Performance Metrics - Over the past six months, the stock has appeared on the Dragon and Tiger list 16 times, with an average price increase of 2.25% the following day and an average increase of 10.78% over five days [3]. - The stock saw a net outflow of 27.61 million yuan in principal funds on the day, with a significant inflow of 92.99 million yuan from large orders [3]. - The latest margin trading data shows a total margin balance of 298 million yuan, with a financing balance of 297 million yuan and a securities lending balance of 447,200 yuan [3].

Group 1 - The core viewpoint of the article highlights that Innovation Medical (002173) experienced a significant stock increase of 10.00% on January 9, with a trading volume of 6.066 billion yuan and a turnover rate of 42.68% [1] - After market hours, data from the Longhu list indicates that the Shenzhen Stock Connect special seat bought 437 million yuan and sold 148 million yuan, resulting in a net purchase of 105 million yuan by one institutional special seat [1]

Group 1 - The core point of the article is that Innovation Medical experienced a significant increase in stock price, rising by 10.00% [1] - The trading volume for Innovation Medical reached 6.066 billion yuan, indicating strong market activity [1] - The turnover rate was reported at 42.68%, suggesting high liquidity in the stock [1] Group 2 - The data from the post-market trading shows that the Shenzhen Stock Connect special seat bought 437 million yuan and sold 148 million yuan [1] - One institutional special seat had a net purchase of 105 million yuan, reflecting institutional interest in the stock [1]